Alvotech Targets Chinese Biosimilars With Yangtze River Deal

Exclusive Partnership Covers Eight Biosimilar Candidates In China

 
• By Dave Wallace

Alvotech has struck a major deal with Yangtze River Pharmaceutical that will allow eight of the biosimilars developer’s products to be commercialized in China.

Business_China
The deal offers access to China for Alvotech’s biosimilars portfolio • Source: Shutterstock

More from Deals

More from Business